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Background: Ataxia telangiectasia (A-T) is a rare but devastating and progressive disorder characterized by
cerebellar dysfunction, lymphoreticular malignancies and recurrent sinopulmonary infections. In A-T, disease of the
respiratory system causes significant morbidity and is a frequent cause of death.
Methods: We used a self-limited murine model of hydrochloric acid-induced acute lung injury (ALI) to determine
the inflammatory answer due to mucosal injury in Atm (A-T mutated)- deficient mice (Atm−/−).
Results: ATM deficiency increased peak lung inflammation as demonstrated by bronchoalveolar lavage fluid (BALF)
neutrophils and lymphocytes and increased levels of BALF pro-inflammatory cytokines (e.g. IL-6, TNF). Furthermore,
bronchial epithelial damage after ALI was increased in Atm−/− mice. ATM deficiency increased airway resistance and
tissue compliance before ALI was performed.
Conclusions: Together, these findings indicate that ATM plays a key role in inflammatory response after airway
mucosal injury.
Keywords: Ataxia telangiectasia, ATM, Acute lung injury, InflammationBackground
Ataxia telangiectasia (A-T) is a severe autosomal reces-
sive disorder that is caused by mutations in the ATM
gene which codes for ataxia telangiectasia mutated
(ATM), a pleiotropic kinase involved in DNA double-
strand break recognition, activation of DNA repair pro-
teins, and signaling in cell cycle checkpoint control
[1-5]. This rare human disease encompasses defects in
T- and B- cell maturation, cerebellar degeneration, radio-
sensitivity, and increased susceptibility to malignancies, es-
pecially lymphomas [6-11]. The majority of patients suffers
from IgA and IgG subclass deficiency and has impaired
antibody responses to pneumococcal antigens [12,13]. Im-
munodeficiency is considered to be the primary factor pre-
disposing these patients to the development of chronic
respiratory tract infections. The 20 year survival rate is
53.4%, and death is predominantly caused by lung failure
and cancer. The prognosis has not changed since 1954 [14].* Correspondence: olaf.eickmeier@kgu.de
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reproduction in any medium, provided the orAtm- deficient (Atm−/−) mice exhibit similar defects as A-T
patients [9,15-19] and have been useful for studying A-T,
mechanisms of DNA damage responses, and oncogenesis.
Lung disease is common in patients with A-T and often
progresses with age and neurological decline [20]. Three
major types of lung disease are generally recognized in A-T
patients: Recurrent sinopulmonary infections and bronchi-
ectasis, interstitial lung disease (ILD)/ pulmonary fibrosis
and lung disease associated with neuromuscular deficits
due to bulbar and spinal system impairment [20-24]. An
evaluation of a series of patients with A-T showed an in-
creased frequency and severity of signs and symptoms of
impaired deglutition and an association between dysphagia,
aspiration and pulmonary disease of these patients was con-
firmed [25]. Clarifying the impact of cellular and clinical fac-
tors on A-T lung disease and its progression may help with
discovery and development of therapeutic interventions.
Aspiration pneumonitis is one of the leading causes of
Acute Lung Injury (ALI)/ Acute Respiratory Distress
Syndrome (ARDS) that is in most instances self-limited,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Survival rate after ALI in Atm−/− and healthy control
mice with different dosing strategies. Survival rate 24 hours after
ALI in Atm−/− (black bars) and control mice (grey bars) after
instillation of 50 μl HCl in comparison to bodyweight adjusted
(1 μl/ g mouse) HCl instillation.
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mechanisms [26]. Here, in a non-lethal model of ALI [27,28],
Atm−/−mice were challenged with intratracheal application of
hydrochloric acid (HCl) in order to examine if host protective
mechanisms are disturbed after mucosal injury.
Methods
Animal model
All mice were maintained under specific pathogen-free
conditions and were checked daily. All studies were
reviewed and approved by the German Animal Subjects
Committee (Gen.Nr.F133/10). We used 10–12 week-old,
male Atm−/− mice (Atmtm1Awb), in a 129SvEv background
[18], kindly provided by A. Wynshaw-Boris, School of
Medicine, University California San Diego, USA, were used
as animal model. Weights of the Atm−/− mice (20 g ±0.4
(n ≥ 5); mean ± S.E.M.) were different from the wild type
animals (24 g ± 0.8; (n ≥ 5); mean ± S.E.M.; p < 0.01).
Acid-initiated acute lung injury (ALI) and treatment with
AT-RVD1
Hydrochloric acid (0.1 N HCl, pH 1.5, 50 μl, endotoxin
free; Sigma-Aldrich) was instilled selectively into the left
mainstem bronchus of anesthetized mice via a 24-gauge
angiocatheter inserted intratracheally. Due to high mortal-
ity rate in the Atm−/− mice, the experimental setting was
changed to instillation of 1 μl/g body weight of 0.1 N HCl
(pH 1.5) into the left mainstem bronchus of anesthetized
mice. At different time points (24 hours and 1 week) after
acid instillation, bilateral bronchoalveolar lavage (BAL) was
performed with 2 aliquots of 1 ml of PBS plus 0.6 mM
EDTA. The total cell counts and leukocyte differential in
BAL fluids (BALFs) were determined as previously de-
scribed [28]. Briefly, total cells in BALFs were counted
using a hemocytometer, and differential cell counts were
determined after cytospin using Wright-Giemsa staining.
Histology and immunohistochemistry
Mice were anesthetized with an intraperitoneal Keta-
min–Rompun mixture (20% Ketamin, CuraMED GmbH,
Karlsruhe, Germany; 8% Rompun, Bayer Vital GmbH,
Leverkusen,Germany) injection. They were perfused trans-
cardially with 4% paraformaldehyde in PBS. Lung tissue
sections were prepared from fixed, paraffin-embedded or-
gans and stained with either hematoxylin and eosin (H&E)
or a special mucous staining, namely Alcian blue and van
Giesona (ABvG).
Measurement of lung mechanics
For measurement of tissue elastance and lung resistance,
mice were anesthetized and mechanically ventilated with
a flexiVent small animal ventilator (SCIREQ, Montreal,
Canada). Lung mechanics were determined in anesthe-
tized, ventilated animals.Mediator levels in BALFs
Select cytokines and chemokines were measured in ali-
quots of BALF by cytometric bead array as described [29].
Statistical analysis
Data are expressed as mean values ± S.E.M. unless other-
wise indicated. A two factorial analysis of variance of the
logarithmized cell counts with interactions was used dis-
criminate between differences caused by experimental
conditions over time and those caused by experimental
groups with the corresponding F test. Gauss distribution
of the residuals was checked with the Shapiro-Wilk test.
Parametric or nonparametric analysis of variance was
used to determine significance for differences between
more than 2 groups as appropriate. For analyses between 2
groups, cohorts were compared by Mann–Whitney-U- test.
Significance was determined with P values ≤ 0.05. Statistics
were performed using GraphPad Prism 5 for Windows
(San Diego, CA, USA).
Results
Atm−/− deficient mice show elevated sensitivity to airway
mucosal injury
In an in vivo setting we examined the role of ATM in
the pathogenesis of airway mucosal injury due to ALI. In
order to measure the inflammatory and resolutional re-
sponse after acute lung injury, 50 μl of hydrochloric acid
(0.1 N HCl, pH 1.5) was instilled into the left mainstem
bronchus. Remarkably, Atm−/−mice showed elevated
mortality due to airway HCl exposure in a defined mild
injury experimental setting [27,28] in comparison to
healthy control mice (Figure 1). A mortality rate of 60%
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rate of 10% in the control group (n > 5) was the reason
for changing the injury protocol. So we adjusted the
acid dosage to the body weight of the mice. In particu-
lar, we injected 1 μl/g body weight of hydrochloric acid
into the left mainstem bronchus and thus increased the
survival rate in the Atm−/−group to 100% (Figure 1).Defective ATM increases leukocyte recruitment after
airway mucosal injury
To determine the effects of ATM on host responses to
mucosal injury, BAL was performed on different time
points after instillation of hydrochloric acid (0.1 N HCl,
pH 1.5) into the left mainstem bronchus (Figure 2a-f
and Figure 3a). There was a significant change in total
BALF cell numbers after ALI (p = 0.017). Total BALF
cell numbers 24 hours after ALI in Atm−/−mice (70.130
total BALF cells ± 14.630 (n = 5); mean ± S.E.M.) were lar-
ger than in healthy control mice (24.840 total BALF cells ±
5898; (n = 4); mean ± S.E.M.) (Figure 3b-d) but this differ-
ence was not significant in two-factorial ANOVA. There
was no significant difference in total leukocyte and differen-
tial cell count between Atm−/− mice before (Figure 3b and
Figure 4a,d,g) or one week after (Figure 3d and Figure 4c,f,
i) ALI. However, 24 hours after injury Atm−/−mice showed
increased BALF neutrophils (PMNs) (30.300 PMNs ±
11.210 (n = 5); mean ± S.E.M.) as compared to healthy
control mice (1.220 PMNs ± 647 (n = 4); mean ± S.E.M.)
(Figure 4b). Difference over time after injury as well asFigure 2 Leukocyte clearance after airway mucosal injury in Atm−/− a
Atm−/− (a) and control mice (d). Atm−/− mice show decreased PMNs cleara
disturbed resolution compared to control mice (e). These differences have
(d-e). Original magnification x100.interactions between Atm−/− mice and control mice were
significant here (p < 0.001 and p = 0.012, respectively).
BALF lymphocytes were also increased in Atm−/−mice
(179 lymphocytes ± 43; (n = 5); mean ± S.E.M.) and in
healthy control mice (34 lymphocytes ± 34, n = 4, mean ±
S.E.M.; p = 0.042 for time-effect in two- factorial ANOVA)
(Figure 4e). There were no significant differences in the
number of macrophages 24 hours after ALI in Atm−/−mice
compared to control mice (Figure 4h).
ATM deficiency impacts the lung histopathological
changes after acid- initiated acute lung injury (ALI)
Acute lung injury due to HCl acid instillation led to in-
creased epithelial disruption 24 hours after exposure to
acid in Atm−/−mice relative to control mice (Figure 5a-d).
One week after mucosal injury Atm−/−mice showed
hyperemic lung tissue (Figure 5e) and increased mucus
production (Figure 5g) in comparison to control mice
(Figure 5f and h).ATM deficient mice show elevated airway resistance and
decreased tissue compliance
To investigate whether ATM deficiency had a measurable
effect on lung mechanics, we determined lung function in
mechanically-ventilated, anesthetized mice. Possibly be-
cause of the unilateral and mild nature of the ALI in this
model, marked changes in airway resistance (Figure 6a)
and tissue compliance (Figure 6b) were not observed and
no significant differences were evident with ATMnd healthy control mice. BALF cell differentiation before ALI between
nce (b) 24 hours after ALI representing increased inflammation and
resolved 1 week after ALI (c and f). Atm−/− mice (a-c), Atm+/+mice
Figure 3 ATM deficiency increases leukocyte recruitment after airway mucosal injury. (a) Atm−/− mice or control mice underwent acute
lung injury (ALI) by intratracheal (i.t.) instillation of HCl and bronchoalveolar lavage (BAL) was performed at different time points. Before ALI (b),
24 hours after ALI (c) and one week after ALI (d) BAL was performed and total cells (b-d) were enumerated (see Methods). Values represent the
mean ± S.E.M. for n≥ 4 mice.
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est, the Atm−/−mice showed increased lung resistance (1.1
cmH2O*s/ml ± 0.12, (n = 5)) and decreased tissue compli-
ance (0.02 cmH2O*/ml ± 0.003, (n = 5)) before mucosal
damage was performed in comparison to control mice (re-
sistance: 0.57 cmH2O*s/ml ± 0.03, mean ± S.E.M., (n = 6),
p < 0.001; compliance (0.04 cmH2O/ml ± 0.002, mean ± S.
E.M., (n = 6), p < 0.005) (Figure 6a and b).
ATM deficiency enhances pro-inflammatory mediator re-
lease after ALI
To identify anti-inflammatory or pro-resolving mecha-
nisms for ATM in ALI, BALF levels of several cytokines
were determined by cytometric bead array. BALF IL-6
(Figure 7a) and TNF-α (Figure 7b) was significantly in-
creased in Atm−/− mice 24 hours after ALI. BALF levels
of other mediators did not increase with Atm deficiency
relative to healthy control mice. No significant changes
were observed in BALF for IL-10, IL-4, IL-12p40, IL-
17A and IFN-γ (data not shown).
Discussion
Lung disease is a common feature in patients with A-T
and often progresses with age and neurological decline
[20]. Diseases of the respiratory system cause significantmorbidity and are a frequent factor or cause of death in
the A-T population [20,30-32]. Several factors contribute
to the increased susceptibility to respiratory infections.
Immunodeficiency may be one, but not the only, etiology
for lung disease in A-T. Low levels of pneumococcal anti-
bodies and diminished levels of IgG subclasses are hall-
marks of A-T and associated with respiratory tract infection
frequency. However, not all respiratory tract infections in
A-T are solely due to immunodeficiency [13,32]. Abnormal
injury repair, premature aging, systemic inflammation, and
oxidative stress are confirmed to contribute to the patho-
physiology and disease progression in A-T lung disease and
pulmonary disorders [33]. However, little is known about
injury and host protective mechanisms in A-T lung disease.
Furthermore, dysphagia in patients with A-T is a well
known clinical symptom [25]. Similar to lung disease, this
problem appears to be progressive and the assumption that
swallowing function worsens with age is consistent with the
progression of neurodegeneration and the bulbar impair-
ments associated with A-T [5]. The impact of cellular and
clinical factors on A-T lung disease is unknown so far. In
our study, we investigated a pathogen-independent damage
in order to determine differences in host mucosal inflam-
matory and repair mechanisms in Atm−/− mice in compari-
son to control mice. Interestingly, Atm−/−mice did not
Figure 4 ATM deficiency increases polymorphonuclear leukocytes (PMNs) and lymphoytes recruitment after airway mucosal injury.
Atm−/− or control mice underwent acute lung injury (ALI) by i.t. instillation of HCl and bronchoalveolar lavage (BAL) was performed at different time
points. Before ALI (a, d, g), 24 hours after ALI (b, e, h) and one week after ALI (c, f, i) BAL was performed and differential cell count for PMNs (a-c),
lymphocytes (d-f) and macrophages (MACs) (g-i) was done. Values represent the mean ± S.E.M. for n≥ 4 mice. * P < 0.05 vs. vehicle group.
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and a slower growth rate compared to the wild-type litter-
mates [34]. However, when challenged with hydrochloric
acid, causing a disruption in the integrity of the airway epi-
thelial barrier, we showed that Atm−/−mice exhibit greater
severity of clinical symptoms and mortality rates as well as
airway recruitment of peripheral leukocytes, and mount an
even stronger immune response characterized by inflam-
matory biomarkers compared with wild-type mice. This
is in accordance with the finding that A-T patients do ex-
hibit elevated serum IL-8 levels, reflecting a systemicinflammation contributing to disease phenotype [35]. Since
weights of the Atm−/−mice were less in comparison to
wild-type mice, initial application of 50 μl hydrochloric acid
may have shown a high mortality rate in Atm−/−mice due
to a higher volume per body weight. So we adjusted the ap-
plication of hydrochloric acid volume to the body weight of
the mice.
Epithelial damage, PMN recruitment and activation of
host protective mechanisms are early events in acute
mucosal inflammation and ALI/ARDS. In this study, we
confirmed the pivotal role of ATM in decreasing the
Figure 5 ATM deficiency impacts the lung histopathological changes after acid –initiated acute lung injury (ALI). Lung tissue sections
were obtained 24 hours after (a-d) and one week after (e-h) ALI from Atm−/− (a, c, e, g) and control mice (b, d, f, h). Hematoxylin and eosin
(H&E) (a, b, e, f) or ABvG (c, d, g, h). Results are representative of n = 3. Black arrowheads, epithelial cell disrupture; white arrowheads, mucus;
black arrows, inflammatory cells. Original magnification x200.
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vored disruption of epithelial barrier integrity after
ALI, as indicated by histological findings, and BALF
biomarkers, namely IL-6 and TNF-α. In addition, we
found an elevation in lung resistance and reduction in
tissue compliance before intratracheal administration
of HCl that was not altered after ALI. This data is in
accordance with pulmonary function testing (PFT) in
A-T patients 12–20 years of age, showing a mixturepattern of obstructive and restrictive lung disease
[21,24,36]. The current study explored for the first time
the inflammatory response of airway mucosa after injury
by HCl. In accordance with human studies showing early
structural changes, particulary bronchiectasis and consoli-
dation [37], our Atm−/−mice showed decreased compli-
ance and increased obstruction before musosal injury
occurred. This is highly suggestive for the role of ATM for
epithelial cell integrity homeostasis.
Figure 6 Elevation in lung resistance and increased tissue compliance in Atm−/− mice before and after mucosal injury. Using a flexiVent
mouse ventilator, (a) tissue resistance and (b) lung compliance were determined before and 24 hours after acid injury. Values represent the
mean ± S.E.M. for n≥ 5 mice. *P < 0.05 vs. control group.
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colitis, or acute inflammation, ATM deficiency also in-
creases production of pro-inflammatory mediators and
regulates leukocyte trafficking to inflammatory sites [38].
Here, ATM deficiency may have contributed to an in-
creased inflammatory response confirmed by levels of
several pro-inflammatory mediators in the injured lung.
On the one hand, neutrophilic invasion into the air-
ways is critical to clear pathogens from the site of infec-
tion and suppression of the inflammatory response may
increase the risk of infection-related adverse events, on
the other hand, neutrophilic activation can cause by-
stander tissue damage that contributes to the pathogen-
esis of ALI/ARDS [39]. To this end, inhibition of PMN
function in animal studies attenuates lung injury induced
by models of gastric acid aspiration [40,41]. In this con-
text our data suggest that ATM is a potent regulator of
mucosal repair and can promote an array of protective
responses for lung catabasis after mucosal injury.Figure 7 Impact of ATM deficiency on inflammatory mediator levels a
week after ALI were analyzed by cytometric bead array (a, b). Values represTogether, the differences of mucosal immune response
and mucosal repair mechanism in Atm−/− mice point to
the clinical impact of repetitive mucosal injury by non-
pathogen associated mucosal damage in order to explain
decline in lung function in our A-T patients. Further-
more, ATM may be a critical immunoregulatory factor
dampening the deleterious effects of acute HCl-induced
inflammation, being mandatory for systemic genomic
stability and homeostasis of the lung epithelial barrier.
Conclusions
Even though the results of our study are more descriptive,
this is the first study showing aggravated non-pathogen
damage response after airway mucosal injury in an in vivo
AT- mouse model.
Atm−/−mice are more sensitive to HCl-induced acute in-
flammation than control mice, especially during remission
(24 hours) and up to one week after lung injury, showing
lack of repair of incurred damage. ATM therefore can befter ALI. Aliquots of BALFs obtained before ALI, 24 hours and one
ent the mean ± S.E.M. for n≥ 3 mice. *P < 0.05 vs. control group.
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airway mucosal damage. Further investigations about the
role of ATM in achieving homeostasis after airway muco-
sal injury may help to understand the pathogenesis of A-T
lung disease.
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